Coartem

Coartem is a brand name of artemether/lumefantrine, approved by the FDA in the following formulation(s):

COARTEM (artemether; lumefantrine - tablet; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: April 7, 2009
  
  Strength(s): 20MG;120MG ^[RLD]

Has a generic version of Coartem been approved?

No. There is currently no therapeutically equivalent version of Coartem available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Coartem. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Antimalarial compositions
  Patent 5,677,331
  Issued: October 14, 1997
  Inventor(s): Zhou; Yiqing & Ning; Dianxi & Wang; Shufen & Ding; Deben & Li; Guofu & Shan; Chengqi & Liu; Guangyu
  Assignee(s): Ciba-Geigy AG
  Institute of Microbiology and Epidemiology, Academy of Military Medical
  The invention relates to a synergistic antimalarial composition which comprises the antimalarial agent benflumetol and also an antimalarial agent from the artemisinine group such as artemether. The composition can be formulated into solid dosage forms such as tablets and is useful for the treatment of drug resistant malaria.
  
  Patent expiration dates:
  
  
  • October 14, 2014
    
    ✓ 
    Patent use: TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • April 7, 2014 - NEW CHEMICAL ENTITY
  
  
  • April 7, 2016 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Coartem Consumer Information (Drugs.com)
• Coartem Consumer Information (Wolters Kluwer)
• Coartem Consumer Information (Cerner Multum)
• Coartem Advanced Consumer Information (Micromedex)
• Coartem AHFS DI Monographs (ASHP)
• Artemether/Lumefantrine Consumer Information (Wolters Kluwer)
• Artemether and lumefantrine Consumer Information (Cerner Multum)
• Artemether and lumefantrine Advanced Consumer Information (Micromedex)
• Artemether and Lumefantrine AHFS DI Monographs (ASHP)